All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The best alternative in the absence of a HLA Matched Sibling Donor (MSD) for patients with Cytogenetically Normal- Acute Myeloid Leukemia (CN-AML) undergoing allogenic Stem Cell Transplantation (SCT) is still under debate.
Motonori Mizutani, from the Aichi Medical University, Nagakute, Japan, and colleagues published a comprehensive retrospective analysis which compared the outcomes of CN-AML patients undergoing Autologous Peripheral Blood Stem Cell Transplantation (auto-PBSCT) and allogeneic Bone Marrow Transplantation (BMT) from a HLA-matched Unrelated Donor (MUD). The results were published in in Biology Blood and Marrow Transplantation on 19th May 2017.
In total, 350 CN-AML patients in First Complete Remission (CR1) who were registered on the Transplant Registry Unified Management Program (TRUMP), were included in this study. Patients either underwent auto-PBSCT (n = 177) or MUD-BMT (n = 173).
In summary, patients transplanted with auto-PBSCT had similar survival outcomes as patients transplanted with MUD-BMT.
The authors concluded by suggesting that “auto-PBSCT remains a viable alternative as post remission therapy” in CN-AML patients in CR1 in the absence of a MSD. The authors further suggested that due to the retrospective nature of their study, their findings should be validated in a prospective study.
Allogeneic stem cell transplantation (SCT) from an HLA-matched sibling donor (MSD) is a post-remission treatment that offers a potential cure for adults with cytogenetically normal acute myeloid leukemia in their first complete remission (CN-AML/CR1). However, the best alternative in the absence of an MSD remains unclear. The aim of this study was to retrospectively compare the outcomes of autologous peripheral blood stem cell transplantation (auto-PBSCT; n = 177) to those of allogeneic bone marrow transplantation from an HLA-matched unrelated donor (MUD-BMT; n = 173) in adult patients with CN-AML/CR1. Both the multivariate analysis (hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.71 to 1.97; P=0.53) and propensity score models (HR, 1.40; 95% CI, 0.80 to 2.43; P = 0.24) indicated that the leukemia-free survival (LFS) rate of auto-PBSCT was not significantly different from that of MUD-BMT. These results suggest that, in the absence of an available MSD, auto-PBSCT remains a viable alternative as post-remission therapy in patients with CN-AML/CR1.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox